Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00460278
Status:
SUSPENDED
Last Update Posted:
2008-06-04
First Post:
2007-04-11
Brief Title:
Study of XL418 in Adults With Solid Tumors
Sponsor:
Exelixis
Organization:
Exelixis
Study Overview
Official Title:
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL418 Administered Orally Daily to Subjects With Solid Tumors
Status:
SUSPENDED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Enrollment suspended due to low drug exposure
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of XL418 in subjects with solid tumors XL418 is a new chemical entity that inhibits a spectrum of targets including Akt and p70S6K that mediate PI3 Kinase PTEN signaling
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None